L’expérimentation du cannabis thérapeutique retardée ? Publié le 15 Mai 2020 https://www.principesactifs.org/lexperimentation-du-cannabis-therapeutique-retardee/ Nonchalance, grèves et coronavirus, l’expérimentation du cannabis thérapeutique a jusqu’ici fait les frais de l’actualité et d’un manque de considération des autorités sanitaires. Alors que plusieurs associations de patients montent au créneau et s’inquiètent d’un éventuel retard, la confirmation de la tenue de l’expérimentation du cannabis thérapeutique en France se fait à demi-mots. Le cannabis médical, une urgence facultative Sur le papier, l’expérimentation du cannabis thérapeutique devait commencer fin 2019. Une première phase de 6 mois consacrée aux modalités de mise en place de l’expérimentation devait initier le processus, suivie par 1 an [...]
Lire la suiteCannabis (Marijuana) : Psychoactive Properties, Addiction, Therapeutic Uses, and Toxicity Sumanasekera W.K. and Spio K. Journal of Addictive Behaviors, Therapy and Rehabilitation, 2016, 5, 2, 1-9. Doi : 10.4172/2324-9005.10001562016 Abstract Background and Objectives : To analyze the existing literature on cannabis (marijuana) under several sub topics; history of use, addiction, mechanism of action, therapeutic uses, and adverse effects. Methods : A comprehensive literature search was conducted. Data sources include original research articles, systematic reviews and meta- analysis, and web-based references such as Drug strategy monographs and Merck Index. Data bases such as PubMed and Cinhal was used. References were from 1979 -2016. Hypothesis : Based on the [...]
Lire la suiteCannabinoids and the Coronavirus Kevin P. Hill Cannabis and Cannabinoid Research, 2020, Volume 5, Number 2, Doi : 10.1089/can.2020.0035 Introduction These are uncertain times as we attempt to manage our lives during the Coronavirus Covid-19 pandemic. It is not surprising, as possible treatments for Covid-19 are discussed, that people wonder about a role for cannabinoids, another topic associated with a lack of clarity about their therapeutic efficacy. Patients commonly ask clinicians about the benefits and risks of cannabinoids and now patients have begun to ask about cannabinoids as they relate to Covid-19. This interest creates an opportunity to strengthen the therapeutic alliance between patients and [...]
Lire la suiteRationale for cannabis-based interventions in the opioid overdose crisis Philippe Lucas Harm Reduction Journal, 2017, 14, 58 Doi : 10.1186/s12954-017-0183-9 Abstract Background : North America is currently in the grips of a crisis rooted in the use of licit and illicit opioid-based analgesics. Drug overdose is the leading cause of accidental death in Canada and the US, and the growing toll of opioid-related morbidity and mortality requires a diversity of novel therapeutic and harm reduction-based interventions. Research suggests that increasing adult access to both medical and recreational cannabis has significant positive impacts on public health and safety as a result of substitution effect. Observational and [...]
Lire la suitePotential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus Mark Feldman, Reem Smoum, Raphael Mechoulam, Doron Steinberg PLoS One, April 15, 2020, 1-13. Doi : 10.1371/journal.pone.0231583 Abstract Infections caused by antibiotic-resistant strains of Staphylococcus aureus have reached epidemic proportions globally. Our previous study showed antimicrobial effects of anandamide (AEA) and arachidonoyl serine (AraS) against methicillin (MET)-resistant S. aureus (MRSA) strains, proposing the therapeutic potential of these endocannabinoid/endocannabinoid-like (EC/EC-like) agents for the treatment of MRSA. Here, we investigated the potential synergism of combinations of AEA and AraS with different types of antibiotics against MRSA grown under planktonic growth or biofilm formation. The most effective [...]
Lire la suiteCannabis Use Patterns and Motives: A Comparison of Younger, Middle-Aged, and Older Medical Cannabis Dispensary Patients Nancy A. Haug, Claudia B. Padula, James E. Sottile, Ryan Vandrey, Adrienne J. Heinz, and Marcel O. Bonn-Miller Addictive Behaviors, 2017, 72, 14-20. Doi : 10.1016/j.addbeh.2017.03.006 Abstract Introduction : Medical cannabis is increasingly being used for a variety of health conditions as more states implement legislation permitting medical use of cannabis. Little is known about medical cannabis use patterns and motives among adults across the lifespan. Methods : The present study examined data collected at a medical cannabis dispensary in San Francisco, California. Participants included 217 medical cannabis patients who [...]
Lire la suiteThe Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosis : A Possible New Concept in the Management of Multiple Sclerosis Symptoms Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto and Lluis Ramió Frontiers in Neurology , 2020 | Volume 11 | Article 152 doi : 10.3389/fneur.2020.00152 Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS symptom can cause or worsen other unwanted symptoms (anticholinergics used for bladder dysfunction produce impairment of cognition, many MS drugs produce erectile dysfunction, etc.). Appropriate symptomatic [...]
Lire la suiteCannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells Nuanying ZHONG, Thesis, Master of Science in Biological Sciences Faculty of Arts and Science, Department of Biological Sciences, University of Lethbridge Research Repository, Canada 2020 https://hdl.handle.net/10133/5697 ABSTRACT Cannabis sativa is an agriculturally and medicinally plant with many pharmaceutical properties. Cancer is a deadly disease; it is estimated that it will cause over 80 thousand deaths in 2019 in Canada. Although numerous studies have demonstrated that cannabinoids have anti-tumorous properties in various cancers, the anti-malignant activities of cannabinol (CBN) on carcinogenesis and underlying mechanisms remain largely unknown. In this study, we [...]
Lire la suiteAppel urgent de la société civile : du cannabis médical pour nos aînés !, signataires, 20 avril 2020
Appel urgent de la société civile : du cannabis médical pour nos aînés ! Nous, associations d’usagers de cannabis à des fins thérapeutiques, médecins et travailleurs sociaux dans le champ des addictions, militants humanitaires appelons solennellement le ministre de la Santé, Olivier Véran, le gouvernement d’Edouard Philippe et le Président de la République, Emmanuel Macron, à rendre possible l’accès immédiat au cannabis à usage médical. Comme l’ont expliqué William Lowenstein et Jean-Yves Nau (Slate du 16 avril 2020), il est choquant que nos anciens reçoivent force benzodiazépines, antidépresseurs, neuroleptiques et opioïdes sans même que l’accès au cannabis à usage thérapeutique soit possible en [...]
Lire la suiteHigh Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn, Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095 Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]
Lire la suite